News
Current report No. 11/2021 – List of shareholders holding at least 5% of the votes at the Extraordinary General Meeting of the Company held on 16 February 2021
February 16, 2021 Legal basis subs. 70 point 3 of the Act on Public Offering – General Shareholder’s Meeting, the above 5% list Content of the report: Acting pursuant to Article 70 point 3 of the Act on Public Offering […] Management Board of Celon Pharma S.A. (the “Company”) hereby informs that the shareholders holdingRead more »
Current report No. 10/2021 – Appointment of a Member of the Supervisory Board
February 16, 2021 Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information Content of the report: Management Board of Celon Pharma S.A. (the “Company”) hereby informs that the Extraordinary General Meeting of the Company held on February 16, 2021 appointed Mr Bogusław Galewski as aRead more »
Current report No. 9/2021 – Resolutions adopted by the Extraordinary General Meeting of Celon Pharma S.A. on February 16, 2021
February 16, 2021 Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical informationContent of the report:Management Board of Celon Pharma S.A. (the “Company”) hereby publishes the text of the resolutions adopted by the Extraordinary General Meeting of the Company on February 16, 2021 along with appendicesRead more »
Current report No. 8/2021 – Resignation of a Member of the Supervisory Board of the Company
February 11, 2021 Subject: Resignation of a Member of the Supervisory Board of the Company Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information Management Board of Celon Pharma S.A. (hereinafter referred to as: the “Company”) informs that on February 11, 2021, Mr. Michał KowalczewskiRead more »
Current report No. 7/2021 – The recommendation of the National Centre for Research and Development to co-fund a project for an inhaled drug candidate for the treatment of inflammatory and fibrotic lung diseases, including COVID-19 complications
February 10, 2021 Date: February 10, 2021, time: 5:42 PM Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – confidential information. Content of the report: Management Board of Celon Pharma S.A. (the “Company”) wishes to announce that on 10 February 2021 it received information that the Company’s application for co-funding ofRead more »
Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL’116, JAK-ROCK Inhibitor.
Celon Pharma S.A. today announced the successful completion of its Phase 1A trial of its JAK/ROCK kinases dual inhibitor, CPL’116. CPL’116 was administered orally in single ascending doses in healthy volunteers in order to assess safety and pharmacokinetic parameters (PK). No adverse events associated with administration of the investigational drug were observed, and the trial metRead more »
Current report No. 6/2021 – Completion of a phase IA clinical trial of a drug based on an innovative JAK/ROCK inhibitor – CPL 409116
February 9, 2021 Date: February 9, 2021, time: 8:56 AM Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – confidential information. In relation to the current report No. 39/2020 of 12 November 2020 on receiving approval for a Phase I clinical trial of a drug based on an innovative JAK/ROCK inhibitorRead more »
Current report No. 6/2021 – Completion of a phase IA clinical trial of a drug based on an innovative JAK/ROCK inhibitor – CPL 409116
Topic: Completion of a phase IA clinical trial of a drug based on an innovative JAK/ROCK inhibitor – CPL 409116 Report content:In relation to the current report No. 39/2020 of 12 November 2020 on receiving approval for a Phase I clinical trial of a drug based on an innovative JAK/ROCK inhibitor – CPL 409116 –Read more »
Current report No. 5/2021 – Dates for submitting periodical reports in 2021
January 29, 2021 Date prepared: 28/01/2021 Subject: Dates for submitting periodical reports in 2021 Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information Content of the report:Acting pursuant to Article 80 subs. 1 of the Regulation of the Minister of Finance of 29 March 2018Read more »
Current report No. 3/2021 – Obtaining a patent for GPR40 receptor agonists and their use in T2D treatment in the US
Subject: Obtaining a patent for GPR40 receptor agonists and their use in T2D treatment in the US Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – confidential information, time: 4:42 PM Content of the report: Management Board of Celon Pharma S.A. (the “Company”) wishes to announce that on January 18, 2021,Read more »